Chelsea Therapeutics International Ltd. believes that an ongoing study of Northera (droxidopa) in Parkinson’s disease patients could fulfill FDA’s request for more data on the norepinephrine prodrug’s efficacy and durability of effect in treating neurogenic orthostatic hypotension (NOH).
However, even if FDA determines that the ongoing trial, known as Study 306, could provide acceptable confirmatory evidence – a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?